Adelaide Research & Scholarship
Statistics
Total Visits
| Views | |
|---|---|
| Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)(legacy) | 197 |
| Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)(legacy) | 87 |
Total Visits per Month
| November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|
| Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R) | 6 | 4 | 3 | 0 | 7 | 3 | 11 |
File Downloads
| Views |
|---|
Top Country Views
| Views | |
|---|---|
| Australia | 72 |
| United States | 43 |
| EU | 18 |
| Netherlands | 8 |
| China | 6 |
| France | 6 |
| Vietnam | 5 |
| Singapore | 4 |
| Argentina | 2 |
| Bulgaria | 1 |
Top City Views
| Views | |
|---|---|
| Kaleen | 51 |
| Ashburn | 14 |
| Rotterdam | 8 |
| Fairfield | 5 |
| Hanoi | 5 |
| Boardman | 3 |
| Dearborn | 2 |
| New York | 2 |
| Singapore | 2 |
| Brisbane | 1 |